[en] Phosphatases and cancer have been related for many years now, as these enzymes regulate key cellular functions, including cell survival, migration, differentiation and proliferation. Dysfunctions or mutations affecting these enzymes have been demonstrated to be key factors for oncogenesis. The aim of this review is to shed light on the role of four different phosphatases (PTEN, PP2A, CDC25 and DUSP1) in five different solid tumors (breast cancer, lung cancer, pancreatic cancer, prostate cancer and ovarian cancer), in order to better understand the most frequent and aggressive primary cancer of the central nervous system, glioblastoma.
Research center :
Giga-Neurosciences - ULiège
Disciplines :
Oncology
Author, co-author :
Dedobbeleer, Matthias ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
Freeman, Stephen ; Université de Liège - ULiège > Département des productions animales (DPA) > GIGA-R : Génomique animale
Goffart, Nicolas
LOMBARD, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Service de neurochirurgie
Rogister, Bernard ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, et biochimie humaine
Language :
English
Title :
Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences
Alternative titles :
[fr] Phosphatases et Tumeurs Solides: Focus sur l'initiation du Glioblastome, la progression et les récurrences
Singh, V., Ram, M., Kumar, R., Prasad, R., Roy, B.K. and Singh, K.K. (2017) Phosphorylation: implications in cancer. Protein J. 36, 1-6 doi:10.1007/s10930-017-9696-z
Rauch, J., Volinsky, N., Romano, D. and Kolch, W. (2011) The secret life of kinases: functions beyond catalysis. Cell Commun. Signal. 9, 23 doi:10.1186/1478-811X-9-23
Douglass, J., Gunaratne, R., Bradford, D., Saeed, F., Hoffert, J.D., Steinbach, P.J. et al. (2012) Identifying protein kinase target preferences using mass spectrometry. Am. J. Physiol. Cell Physiol. 303, C715-C727 doi:10.1152/ajpcell.00166.2012
Stebbing, J., Lit, L.C., Zhang, H., Darrington, R.S., Melaiu, O., Rudraraju, B. et al. (2014) The regulatory roles of phosphatases in cancer. Oncogene 33, 939-953 doi:10.1038/onc.2013.80
Carlsson, S.K., Brothers, S.P. and Wahlestedt, C. (2014) Emerging treatment strategies for glioblastoma multiforme. EMBO Mol. Med. 6, 1359-1370 doi:10.15252/emmm.201302627
Naumann, U., Harter, P., Rubel, J., Ilina, E., Blank, A.-E., Esteban, H. et al. (2013) Glioma cell migration and invasion as potential target for novel treatment strategies. Transl. Neurosci. 4, 314-329 doi:10.2478/s13380-013-0126-1
Ostrom, Q.T., Bauchet, L., Davis, F.G., Deltour, I., Fisher, J.L., Langer, C.E. et al. (2014) The epidemiology of glioma in adults: a 'state of the science' review. Neuro-oncology 16, 896-913 doi:10.1093/neuonc/nou087
Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K. et al. (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131, 803-820 doi:10.1007/s00401-016-1545-1
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G. and Von Deimling, A. (2015) Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol. 129, 829-848 doi:10.1007/s00401-015-1432-1
Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D. et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157-173 doi:10.1016/j.ccr.2006.02.019
Verhaak, R.G.W., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D. et al. (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 doi:10.1016/j.ccr.2009.12.020
Ceccarelli, M., Barthel, F.P., Malta, T.M., Sabedot, T.S., Salama, S.R., Murray, B.A. et al. (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164, 550-563 doi:10.1016/j.cell.2015.12.028
Mallick, S., Benson, R., Hakim, A. and Rath, G.K. (2016) Management of glioblastoma after recurrence: a changing paradigm. J. Egypt. Natl Canc. Inst. 28, 199-210 doi:10.1016/j.jnci.2016.07.001
Singh, S.K., Clarke, I.D., Terasaki, M., Bonn, V.E., Hawkins, C., Squire, J. et al. (2003) Identification of a cancer stem cell in human brain tumors identification of a cancer stem cell in human brain tumors. Cancer Res. 15, 5821-5828 PMID:14522905
Bradshaw, A., Wickremsekera, A., Tan, S.T., Peng, L., Davis, P.F. and Itinteang, T. (2016) Cancer stem cell hierarchy in glioblastoma multiforme. Front. Surg. 3, 21 doi:10.3389/fsurg.2016.00021
Lathia, J.D., Mack, S.C., Mulkearns-Hubert, E.E., Valentim, C.L.L. and Rich, J.N. (2015) Cancer stem cells in glioblastoma. Genes Dev. 29, 1203-1217 doi:10.1101/gad.261982.115
Lathia, J.D., Venere, M., Rao, M.S. and Rich, J.N. (2011) Seeing is believing: are cancer stem cells the loch ness monster of tumor biology. Stem Cell Rev. Rep. 7, 227-237 doi:10.1007/s12015-010-9194-6
Goffart, N., Dedobbeleer, M. and Rogister, B. (2014) Glioblastoma stem cells: new insights in therapeutic strategies. Fut. Neurol. 9, 1-15 doi:10.2217/ fnl.14.56
Shi, Y. (2009) Serine/threonine phosphatases: mechanism through structure. Cell 139, 468-484 doi:10.1016/j.cell.2009.10.006
Simpson, L. and Parsons, R. (2001) PTEN: life as a tumor suppressor. Exp. Cell Res. 264, 29-41 doi:10.1006/excr.2000.5130
Wang, S.I., Puc, J., Li, J., Bruce, J.N., Cairns, P., Sidransky, D. et al. (1997) Somatic mutations of PTEN in glioblastoma multiforme advances in brief somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 57, 4183-4186 PMID:9331071
Hopkins, B.D., Hodakoski, C., Barrows, D., Mense, S.M. and Parsons, R.E. (2014) PTEN function: the long and the short of it. Trends Biochem. Sci. 39, 183-190 doi:10.1016/j.tibs.2014.02.006
Endersby, R. and Baker, S.J. (2008) PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 5416-5430 doi:10.1038/onc.2008.239
Koul, D. (2008) PTEN signaling pathways in glioblastoma. Cancer Biol. Ther. 7, 1321-1325 doi:10.4161/cbt.7.9.6954
Carico, C., Nuño, M., Mukherjee, D., Elramsisy, A., Dantis, J., Hu, J. et al. (2012) Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide era. PLoS ONE 7, e33684 doi:10.1371/journal.pone.0033684
Xu, J., Li, Z., Wang, J., Chen, H. and Fang, J.-Y. (2014) Combined PTEN mutation and protein expression associate with overall and disease-free survival of glioblastoma patients. Transl. Oncol. 7, 196-205.e1 doi:10.1016/j.tranon.2014.02.004
Arif, S.H., Pandith, A.A., Bhat, A.R., Ramzan, A.U., Malik, N.K., Chibber, S.S. et al. (2015) EGFR and PTEN gene mutation status in glioblastoma patients and their prognostic impact on patient's survival. J. Carcinog. Mutagen. 6, 218 doi:10.4172/2157-2518.1000218
Yang, Y., Shao, N., Luo, G., Li, L., Zheng, L., Nilsson-Ehle, P. et al. (2010) Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate. Anticancer Res. 30, 981-985 PMID:20393024
Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A. et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114, 97-109 doi:10.1007/s00401-007-0243-4
Huse, J.T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S.H. et al. (2009) The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 23, 1327-1337 doi:10.1101/gad.1777409
Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y. et al. (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol. 57, 684-689 doi:10.1097/00005072-199807000-00005
Sturm, D., Bender, S., Jones, D.T.W., Lichter, P., Grill, J., Becher, O. et al. (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer 14, 92-107 doi:10.1038/nrc3655
Shukla, S., Pia Patric, I.R., Thinagararjan, S., Srinivasan, S., Mondal, B., Hegde, A.S. et al. (2013) A DNA methylation prognostic signature of glioblastoma: identification of NPTX2-PTEN-NF-B nexus. Cancer Res. 73, 6563-6573 doi:10.1158/0008-5472.CAN-13-0298
Li, L., Dutra, A., Pak, E., Labrie, J.E., Gerstein, R.M., Pandolfi, P.P. et al. (2008) EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro-oncology 11, 9-21 doi:10.1215/15228517-2008-081
Lv, S., Teugels, E., Sadones, J., De Brakeleer, S., Duerinck, J., Du Four, S. et al. (2012) Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int. J. Oncol. 41, 1029-1035 doi:10.3892/ijo.2012.1539
Davies, E.M., Kong, A.M., Tan, A., Gurung, R., Sriratana, A., Bukczynska, P.E. et al. (2015) Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration. Oncogene 34, 3711-3727 doi:10.1038/onc.2014.303
Sun, Z., Huang, C., He, J., Lamb, K.L., Kang, X., Gu, T. et al. (2014) PTEN C-Terminal deletion causes genomic instability and tumor development. Cell Rep. 6, 844-854 doi:10.1016/j.celrep.2014.01.030
McEllin, B., Camacho, C.V., Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R.M. et al. (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457-5464 doi:10.1158/0008-5472.CAN-09-4295
Lin, F., de Gooijer, M.C., Roig, E.M., Buil, L.C.M., Christner, S.M., Beumer, J.H. et al. (2014) ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin. Cancer Res. 20, 2703-2713 doi:10.1158/1078-0432.CCR-14-0084
Ho Yang, S., Li, S., Lu, G., Xue, H., Kim, D.H., Zhu, J.-J. et al. (2016) Metformin treatment reduces temozolomide resistance of glioblastoma cells. Oncotarget 7, 78787-78803 doi:10.18632/oncotarget.12859
Sesen, J., Dahan, P., Scotland, S.J., Saland, E., Dang, V.-T., Lemarié, A. et al. (2015) Metformin inhibits growth of human glioblastoma cells and enhances therapeutic response. PLoS ONE 10, e0123721 doi:10.1371/journal.pone.0123721
Xu, W., Bi, Y., Kong, J., Zhang, J., Wang, B., Li, K. et al. (2016) Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+PTEN-glioblastoma in vivo. Oncotarget 7, 24752-24765 doi:10.18632/oncotarget.8407
Lester, A., Rapkins, R., Nixdorf, S., Khasraw, M. and McDonald, K. (2017) Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: is PTEN predictive of response? Clin. Transl. Oncol. 19, 273-278 doi:10.1007/s12094-016-1547-4
Yin, Y. and Shen, W.H. (2008) PTEN: a new guardian of the genome. Oncogene 27, 5443-5453 doi:10.1038/onc.2008.241
Shen, W.H., Balajee, A.S., Wang, J., Wu, H., Eng, C., Pandolfi, P.P. et al. (2007) Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157-170 doi:10.1016/j.cell.2006.11.042
Zhang, Z., Hou, S.-Q., He, J., Gu, T., Yin, Y. and Shen, W.H. (2016) PTEN regulates PLK1 and controls chromosomal stability during cell division. Cell Cycle 15, 2476-2485 doi:10.1080/15384101.2016.1203493
Zhang, L., Zhang, S., Yao, J., Lowery, F.J., Zhang, Q., Huang, W.-C. et al. (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527, 100-104 doi:10.1038/nature15376
Ren, P., Gong, F., Zhang, Y., Jiang, J. and Zhang, H. (2016) MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumour Biol. 37, 3215-3225 doi:10.1007/s13277-015-4150-3
Lei, L., Huang, Y. and Gong, W. (2013) miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol. Rep. 30, 2897-2902 doi:10.3892/or.2013.2755
Yang, Z., Fang, S., Di, Y., Ying, W., Tan, Y., Gu, W. et al. (2015) Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin. PLoS ONE 10, e0121547 doi:10.1371/journal.pone.0121547
Xie, X., Liu, H.T., Mei, J., Ding, F.B., Xiao, H.B., Hu, F.Q. et al. (2015) miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. Int. J. Clin. Exp. Pathol. 8, 3827-3834 PMID:26097565
Guo, P., Nie, Q., Lan, J., Ge, J., Qiu, Y. and Mao, Q. (2013) C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells. Biochem. Biophys. Res. Commun. 441, 186-190 doi:10.1016/j.bbrc.2013.10.034
Xia, X., Li, Y., Wang, W., Tang, F., Tan, J., Sun, L. et al. (2015) MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Mol. Cancer 14, 154 doi:10.1186/s12943-015-0423-0
Li, H. and Yang, B.B. (2013) Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol. Sin. 34, 870-879 doi:10.1038/aps. 2013.35
Ames, H., Halushka, M.K. and Rodriguez, F.J. (2017) miRNA regulation in gliomas: usual suspects in glial tumorigenesis and evolving clinical applications. J. Neuropathol. Exp. Neurol. 76, 246-254 doi:10.1093/jnen/nlx005
Ciuffreda, L., Falcone, I., Cesta Incani, U., Del Curatolo, A., Conciatori, F., Matteoni, S. et al. (2014) PTEN expression and function in adult cancer stem cells and prospects for therapeutic targeting. Adv. Biol. Regul. 56, 66-80 doi:10.1016/j.jbior.2014.07.002
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J. et al. (2003) Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 doi:10.1016/S1535-6108(03)00215-0
Hill, R. and Wu, H. (2009) PTEN, stem cells, and cancer stem cells. J. Biol. Chem. 284, 11755-11759 doi:10.1074/jbc.R800071200
Mulholland, D.J., Kobayashi, N., Ruscetti, M., Zhi, A., Tran, L.M., Huang, J. et al. (2012) Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res. 72, 1878-1889 doi:10.1158/0008-5472.CAN-11-3132
Zhou, J., Wulfkuhle, J., Zhang, H., Gu, P., Yang, Y., Deng, J. et al. (2007) Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl Acad. Sci. U.S.A. 104, 16158-16163 doi:10.1073/pnas.0702596104
Ebbesen, S.H., Scaltriti, M., Bialucha, C.U., Morse, N., Kastenhuber, E.R., Wen, H.Y. et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc. Natl Acad. Sci. U.S.A. 113, 3030-3035 doi:10.1073/pnas.1523693113
Groszer, M., Erickson, R., Scripture-Adams, D.D., Dougherty, J.D., Le Belle, J., Zack, J.A. et al. (2006) PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc. Natl Acad. Sci. U.S.A. 103, 111-116 doi:10.1073/pnas.0509939103
Duan, S., Yuan, G., Liu, X., Ren, R., Li, J., Zhang, W. et al. (2015) PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat. Commun. 6, 10068 doi:10.1038/ncomms10068
Pandey, P., Seshacharyulu, P., Das, S., Rachagani, S., Ponnusamy, M.P., Yan, Y. et al. (2013) Impaired expression of protein phosphatase 2A subunits enhances metastatic potential of human prostate cancer cells through activation of AKT pathway. Br. J. Cancer 108, 2590-2600 doi:10.1038/bjc.2013.160
Loveday, C., Tatton-Brown, K., Clarke, M., Westwood, I., Renwick, A., Ramsay, E. et al. (2015) Mutations in the PP2A regulatory subunit B family genes PPP2R5B, PPP2R5C and PPP2R5D cause human overgrowth. Hum. Mol. Genet. 24, 4775-4779 doi:10.1093/hmg/ddv182
Eichhorn, P.J.A., Creyghton, M.P. and Bernards, R. (2009) Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta Rev. Cancer 1795, 1-15 doi:10.1016/j.bbcan.2008.05.005
Sangodkar, J., Farrington, C.C., McClinch, K., Galsky, M.D., Kastrinsky, D.B. and Narla, G. (2016) All roads lead to PP2A: exploiting the therapeutic potential of this phosphatase. FEBS J. 283, 1004-1024 doi:10.1111/febs.13573
Rincón, R., Cristóbal, I., Zazo, S., Arpí, O., Menéndez, S., Manso, R. et al. (2015) PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects. Oncotarget 6, 4299-4314 doi:10.18632/oncotarget.3012
He, K., Shi, L., Jiang, T., Li, Q., Chen, Y. and Meng, C. (2016) Association between SET expression and glioblastoma cell apoptosis and proliferation. Oncol. Lett. 12, 2435-2444 doi:10.3892/ol.2016.4951
Yi, F., Ni, W., Liu, W., Bai, J. and Li, W. (2013) Expression and biological role of CIP2A in human astrocytoma. Mol. Med. Rep. 7, 1376-1380 doi:10.3892/mmr.2013.1357
Janghorban, M., Farrell, A.S., Allen-Petersen, B.L., Pelz, C., Daniel, C.J., Oddo, J. et al. (2014) Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc. Natl Acad. Sci. U.S.A. 111, 9157-9162 doi:10.1073/pnas.1317630111
Liu, H., Gu, Y., Wang, H., Yin, J., Zheng, G. and Zhang, Z. (2015) Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer. Oncotarget 6, 14913-14925 doi:10.18632/oncotarget.3818
Grech, G., Baldacchino, S., Saliba, C., Grixti, M.P., Gauci, R., Petroni, V. et al. (2016) Deregulation of the protein phosphatase 2A, PP2A in cancer: complexity and therapeutic options. Tumor Biol. 37, 11691-11700 doi:10.1007/s13277-016-5145-4
Swingle, M., Ni, L. and Honkanen, R.E. (2007) Small-molecule inhibitors of ser/thr protein phosphatases: specificity, use and common forms of abuse. Methods Mol. Biol. 365, 23-38 doi:10.1385/1-59745-267-X:23
Castigli, E., Sciaccaluga, M., Schiavoni, G., Brozzi, F., Fabiani, R., Gorello, P. et al. (2006) GL15 and U251 glioblastoma-derived human cell lines are peculiarly susceptible to induction of mitotic death by very low concentrations of okadaic acid. Oncol. Rep. 15, 463-470 PMID:16391870
Lu, J., Kovach, J.S., Johnson, F., Chiang, J., Hodes, R., Lonser, R. et al. (2009) Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanisms. Proc. Natl Acad. Sci. U.S.A. 106, 11697-11702 doi:10.1073/pnas.0905930106
Han, X., Xu, B., Beevers, C.S., Odaka, Y., Chen, L., Liu, L. et al. (2012) Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis 33, 868-875 doi:10.1093/carcin/bgs029
Li, J.-y., Huang, J.-y., Li, M., Zhang, H., Xing, B., Chen, G. et al. (2012) Anisomycin induces glioma cell death via down-regulation of PP2A catalytic subunit in vitro. Acta Pharmacol. Sin. 33, 935-940 doi:10.1038/aps.2012.46
Puustinen, P., Junttila, M.R., Vanhatupa, S., Sablina, A.A., Hector, M.E., Teittinen, K. et al. (2009) PME-1 protects extracellular signal-regulated kinase pathway activity from protein phosphatase 2A-mediated inactivation in human malignant glioma. Cancer Res. 69, 2870-2877 doi:10.1158/0008-5472. CAN-08-2760
Kaur, A., Denisova, O.V., Qiao, X., Jumppanen, M., Peuhu, E., Ahmed, S.U. et al. (2016) PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells. Cancer Res. 76, 7001-7011 doi:10.1158/0008-5472.CAN-16-1134
Hong, C.S., Ho, W., Zhang, C., Yang, C., Elder, J.B. and Zhuang, Z. (2015) LB100, a small molecule inhibitor of PP2A with potent chemo-and radio-sensitizing potential. Cancer Biol. Ther. 16, 821-833 doi:10.1080/15384047.2015.1040961
Gordon, I.K., Lu, J., Graves, C.A., Huntoon, K., Frerich, J.M., Hanson, R.H. et al. (2015) Protein phosphatase 2A inhibition with LB100 enhances radiationinduced mitotic catastrophe and tumor growth delay in glioblastoma. Mol. Cancer Ther. 14, 1540-1547 doi:10.1158/1535-7163.MCT-14-0614
Chung, V., Mansfield, A.S., Braiteh, F., Richards, D., Durivage, H., Ungerleider, R.S. et al. (2017) Cancer therapy: clinical safety, tolerability, and preliminary activity of LB-100, an inhibitor of protein phosphatase 2A, in patients with relapsed solid tumors: an open-label, dose escalation, first-in-human, phase I trial. Clin. Cancer Res. 1-8 doi:10.1158/1078-0432.CCR-16-2299
Farrell, A.S., Allen-petersen, B., Daniel, C.J., Wang, X., Wang, Z., Rodriguez, S. et al. (2015) Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol. Cancer Res. 12, 924-939 doi:10.1158/1541-7786.MCR-13-0542
Chien, W., Sun, Q.-Y., Lee, K.L., Ding, L.-W., Wuensche, P., Torres-Fernandez, L.A. et al. (2015) Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol. Oncol. 9, 889-905 doi:10.1016/j.molonc.2015.01.002
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G. et al. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov. 9, 883-897 doi:10.1038/nrd3248
Sonoda, Y., Yamamoto, D., Sakurai, S., Hasegawa, M., Aizu-Yokota, E., Momoi, T. et al. (2001) FTY720, a novel immunosuppressive agent, induces apoptosis in human glioma cells. Biochem. Biophys. Res. Commun. 281, 282-288 doi:10.1006/bbrc.2001.4352
Zhang, L., Wang, H., Zhu, J., Ding, K. and Xu, J. (2014) FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K/AKT/mTOR/p70S6K signaling pathway. Tumor Biol. 35, 10707-10714 doi:10.1007/s13277-014-2386-y
Zhang, L., Wang, H., Ding, K. and Xu, J. (2015) FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells. Toxicol. Lett. 236, 43-59 doi:10.1016/j.toxlet.2015.04.015
Cipriani, R., Chara, J.C., Rodríguez-Antigüedad, A. and Matute, C. (2015) FTY720 attenuates excitotoxicity and neuroinflammation. J. Neuroinflammation 12, 86 doi:10.1186/s12974-015-0308-6
Sharim, J., Tashjian, R., Golzy, N. and Pouratian, N. (2016) Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. J. Clin. Neurosci. 30, 166-168 doi:10.1016/j.jocn.2016.02.003
White, C., Alshaker, H., Cooper, C., Winkler, M. and Pchejetski, D. (2016) The emerging role of FTY720 (Fingolimod) in cancer treatment. Oncotarget 7, 23106-23127 doi:10.18632/oncotarget.7145
Berggren, M., Sittadjody, S., Song, Z., Samira, J.-L., Burd, R. and Meuillet, E.J. (2009) Sodium selenite increases the activity of the tumor suppressor protein, PTEN, in DU-145 prostate cancer cells. Nutr. Cancer 61, 322-331 doi:10.1080/01635580802521338
Chen, P., Wang, L., Li, N., Liu, Q. and Ni, J. (2013) Comparative proteomics analysis of sodium selenite-induced apoptosis in human prostate cancer cells. Metallomics 5, 541-550 doi:10.1039/c3mt00002h
Chen, T.-I., Chiu, H.-W., Pan, Y.-C., Hsu, S.-T., Lin, J.-H. and Yang, K.-T. (2014) Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation. J. Biomed. Sci. 21, 46 doi:10.1186/1423-0127-21-46
Yan, Y., Cao, P.T., Greer, P.M., Nagengast, E.S., Kolb, R.H., Mumby, M.C. et al. (2010) Protein phosphatase 2A has an essential role in the activation of γ-irradiation-induced G2/M checkpoint response. Oncogene 29, 4317-4329 doi:10.1038/onc.2010.187
Hofstetter, C.P., Burkhardt, J.K., Shin, B.J., Gürsel, D.B., Mubita, L., Gorrepati, R. et al. (2012) Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia. PLoS ONE 7, e30059 doi:10.1371/journal.pone.0030059
Lu, J., Zhuang, Z., Song, D.K., Mehta, G.U., Ikejiri, B., Mushlin, H. et al. (2010) The effect of a PP2A inhibitor on the nuclear receptor corepressor pathway in glioma. J. Neurosurg. 113, 225-233 doi:10.3171/2009.11.JNS091272
Estrada-Bernal, A., Palanichamy, K., Ray Chaudhury, A. and Van Brocklyn, J.R. (2012) Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma. Neuro-Oncology 14, 405-415 doi:10.1093/neuonc/nos005
Marfia, G., Campanella, R., Navone, S.E., Di Vito, C., Riccitelli, E., Hadi, L.A. et al. (2014) Autocrine/paracrine sphingosine-1-phosphate fuels proliferative and stemness qualities of glioblastoma stem cells. Glia 62, 1968-1981 doi:10.1002/glia.22718
Gürsel, D.B., Banu, M.A., Berry, N., Marongiu, R., Burkhardt, J.-K., Kobylarz, K. et al. (2015) Tight regulation between cell survival and programmed cell death in GBM stem-like cells by EGFR/GSK3b/PP2A signaling. J. Neurooncol. 121, 19-29 doi:10.1007/s11060-014-1602-3
Le Guelte, A., Galan-Moya, E.-M., Dwyer, J., Treps, L., Kettler, G., Hebda, J.K. et al. (2012) Semaphorin 3A elevates endothelial cell permeability through PP2A inactivation. J. Cell Sci. 125, 4137-4146 doi:10.1242/jcs.108282
Sur, S. and Agrawal, D.K. (2016) Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategies. Mol. Cell. Biochem. 416, 33-46 doi:10.1007/s11010-016-2693-2
Nakabayashi, H., Hara, M. and Shimizu, K. (2006) Prognostic significance of CDC25B expression in gliomas. J. Clin. Pathol. 59, 725-728 doi:10.1136/jcp.2005.029546
Yamashita, Y., Kasugai, I., Sato, M., Tanuma, N., Sato, I., Nomura, M. et al. (2010) CDC25A mRNA levels significantly correlate with Ki-67 expression in human glioma samples. J. Neurooncol. 100, 43-49 doi:10.1007/s11060-010-0147-3
Liang, J., Cao, R., Zhang, Y., Xia, Y., Zheng, Y., Li, X. et al. (2016) PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nat. Commun. 7, 12431 doi:10.1038/ncomms12431
Liberti, M.V. and Locasale, J.W. (2016) The Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 211-218 doi:10.1016/j.tibs.2015.12.001
Ngan, E.S.W., Hashimoto, Y., Ma, Z.-Q., Tsai, M.-J. and Tsai, S.Y. (2003) Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 22, 734-739 doi:10.1038/sj.onc.1206121
Ta, H.Q., Ivey, M.L., Frierson, H.F., Conaway, M.R., Dziegielewski, J., Larner, J.M. et al. (2015) Checkpoint Kinase 2 negatively regulates Androgen sensitivity and prostate cancer cell growth. Cancer Res. 75, 5093-5105 doi:10.1158/0008-5472.CAN-15-0224
Chou, Y.-W., Zhang, L., Muniyan, S., Ahmad, H., Kumar, S., Alam, S.M. et al. (2013) Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathways. PLoS ONE 8, e61934 doi:10.1371/journal.pone.0061934
Broggini, M., Buraggi, G., Brenna, A., Riva, L., Codegoni, A.M., Torri, V. et al. (2000) Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res. 20, 4835-4840 PMID:11205229
Wu, W., Fan, Y.H., Kemp, B.L., Walsh, G. and Mao, L. (1998) Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 58, 4082-4085 PMID:9751615
Sasaki, H., Yukiue, H., Kobayashi, Y., Tanahashi, M., Moriyama, S., Nakashima, Y. et al. (2001) Expression of the cdc25B gene as a prognosis marker in non-small cell lung cancer. Cancer Lett. 173, 187-192 doi:10.1016/S0304-3835(01)00669-3
Boldrini, L., Gisfredi, S., Ursino, S., Lucchi, M., Mussi, A. and Fontanini, G. (2007) CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Hum. Pathol. 38, 1563-1568 doi:10.1016/j.humpath.2007.03.006
Li, J., Yang, C.X., Mei, Z.-J., Chen, J., Zhang, S.-M., Sun, S.-X. et al. (2013) Involvement of Cdc25c in cell cycle alteration of a radioresistant lung cancer cell line established with fractionated ionizing radiation. Asian Pacific J. Cancer Prev. 14, 5725-5730 doi:10.7314/APJCP.2013.14.10.5725
Galaktionov, K., Lee, A., Eckstein, J., Draetta, G., Meckler, J., Loda, M. et al. (1995) CDC25 phosphatases as potential human oncogenes. Science 269, 1575-1577 doi:10.1126/science.7667636
Löffler, H., SyljuAsen, R.G., Bartkova, J., Worm, J., Lukas, J. and Bartek, J. (2003) Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines. Oncogene 22, 8063-8071 doi:10.1038/sj.onc.1206976
Cangi, M.G., Cukor, B., Soung, P., Signoretti, S., Moreira, G., Ranashinge, M. et al. (2000) Role of the Cdc25A phosphatase in human breast cancer. J. Clin. Invest. 106, 753-761 doi:10.1172/JCI9174
Ito, Y., Yoshida, H., Uruno, T., Takamura, Y., Miya, A., Kuma, K. et al. (2004) Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11, 295-300 doi:10.1007/BF02984552
Sengupta, S., Jana, S. and Bhattacharyya, A. (2014) TGF-β-Smad2 dependent activation of CDC 25A plays an important role in cell proliferation through NFAT activation in metastatic breast cancer cells. Cell. Signal. 26, 240-252 doi:10.1016/j.cellsig.2013.11.013
Hirose, Y., Berger, M.S. and Pieper, R.O. (2001) Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 61, 5843-5849 PMID:11479224
De Witt Hamer, P.C., Mir, S.E., Noske, D., Van Noorden, C.J.F. and Würdinger, T. (2011) WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17, 4200-4207 doi:10.1158/1078-0432.CCR-10-2537
Gutierrez, G.J., Tsuji, T., Cross, J.V., Davis, R.J., Templeton, D.J., Jiang, W. et al. (2010) JNK-mediated phosphorylation of Cdc25C regulates cell cycle entry and G2/M DNA damage checkpoint. J. Biol. Chem. 285, 14217-14228 doi:10.1074/jbc.M110.121848
Lazo, J.S. and Wipf, P. (2008) Is Cdc25 a druggable target?. Anticancer Agents Med. Chem. 8, 837-842 doi:10.2174/187152008786847738
Nemoto, K. (2010) G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2). Exp. Ther. Med. 1, 647-650 doi:10.3892/etm-00000101
Brezak, M.-C., Valette, A., Quaranta, M., Contour-Galcera, M.-O., Jullien, D., Lavergne, O. et al. (2009) IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. Int. J. Cancer 124, 1449-1456 doi:10.1002/ijc.24080
Ding, W., Hu, Z., Zhang, Z., Ma, Q., Tang, H. and Ma, Z. (2015) Physapubescin B exhibits potent activity against human prostate cancer in vitro and in vivo. J. Agric. Food Chem. 63, 9504-9512 doi:10.1021/acs.jafc.5b03045
Bana, E., Sibille, E., Valente, S., Cerella, C., Chaimbault, P., Kirsch, G. et al. (2015) A novel coumarin-quinone derivative SV37 inhibits CDC25 phosphatases, impairs proliferation, and induces cell death. Mol. Carcinogen. 54, 229-241 doi:10.1002/mc.22094
Falck, J., Mailand, N., SyljuAsen, R.G., Bartek, J. and Lukas, J. (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 doi:10.1038/35071124
Xu, X., Fan, Z., Liang, C., Li, L., Wang, L., Liang, Y. et al. (2017) A signature motif in LIM proteins mediates binding to checkpoint proteins and increases tumour radiosensitivity. Nat. Commun. 8, 14059 doi:10.1038/ncomms14059
Forte, S., Pagliuca, A., Maniscalchi, E.T., Gulino, R., Calabrese, G., Ricci-Vitiani, L. et al. (2013) Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. PLoS ONE 8, e81432 doi:10.1371/journal.pone.0081432
Fidoamore, A., Cristiano, L., Antonosante, A., d'Angelo, M., Di Giacomo, E., Astarita, C. et al. (2016) Glioblastoma stem cells microenvironment: the paracrine roles of the niche in drug and radioresistance. Stem. Cells Int. 2016, 1-17 doi:10.1155/2016/6809105
Lau, L.F. and Nathans, D. (1985) Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. EMBO J. 4, 3145-3151 PMID:3841511
Sun, H., Charles, C.H., Lau, L.F. and Tonks, N.K. (1993) MKP-1 (3CH134), an immediate early gene product, is a dual specificity phosphatase that dephosphorylates MAP kinase in vivo. Cell 75, 487-493 doi:10.1016/0092-8674(93)90383-2
Patterson, K.I., Brummer, T., O'brien, P.M. and Daly, R.J. (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 418, 475-489 doi:10.1042/BJ20082234
Sharma, A.K., Mansukh, A., Varma, A., Gadewal, N. and Gupta, S. (2013) Molecular modeling of differentially phosphorylated serine 10 and acetylated lysine 9/14 of histone H3 regulates their interactions with 14-3-3 ζ, MSK1, and MKP1. Bioinform. Biol. Insights 7, 271-288 doi:10.4137/BBI.S12449
Caunt, C.J. and Keyse, S.M. (2013) Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J. 280, 489-504 doi:10.1111/j.1742-4658.2012.08716.x
Loda, M., Capodieci, P., Mishra, R., Yao, H., Corless, C., Grigioni, W. et al. (1996) Expression of mitogen-activated protein kinase phosphatase-1 in the early phases of human epithelial carcinogenesis. Am. J. Pathol. 149, 1553-1564 PMID:8909245
Liao, Q., Guo, J., Kleeff, J., Zimmermann, A., Bechler, M.W., Korc, M. et al. (2003) Down-regulation of the dual-specificity phosphatase MKP-1 suppresses tumorigenicity of pancreatic cancer cells. Gastroenterology 124, 1830-1845 doi:10.1016/S0016-5085(03)00398-6
Vicent, S., Garayoa, M., López-Picazo, J.M., Lozano, M.D., Toledo, G., Thunnissen, F.B.J.M. et al. (2004) Mitogen-activated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin. Cancer Res. 10, 3639-3649 doi:10.1158/1078-0432.CCR-03-0771
Moncho-Amor, V., Ibañez de Cáceres, I., Bandres, E., Martínez-Poveda, B., Orgaz, J.L., Sánchez-Pérez, I. et al. (2011) DUSP1/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene 30, 668-678 doi:10.1038/onc.2010.449
Gil-Araujo, B., Toledo Lobo, M.-V., Gutiérrez-Salmerón, M., Gutiérrez-Pitalúa, J., Ropero, S., Angulo, J.C. et al. (2014) Dual specificity phosphatase 1 expression inversely correlates with NF-κB activity and expression in prostate cancer and promotes apoptosis through a p38 MAPK dependent mechanism. Mol. Oncol. 8, 27-38 doi:10.1016/j.molonc.2013.08.012
Magi-Galluzzi, C., Mishra, R., Fiorentino, M., Montironi, R., Yao, H., Capodieci, P. et al. (1997) Mitogen-activated protein kinase phosphatase 1 is overexpressed in prostate cancers and is inversely related to apoptosis. Lab. Invest. 76, 37-51 PMID:9010448
Srikanth, S., Franklin, C.C., Duke, R.C. and Kraft, A.S. (1999) Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis. Mol. Cell. Biochem. 199, 169-178 doi:10.1023/A:1006980326855
Rauhala, H.E., Porkka, K.P., Tolonen, T.T., Martikainen, P.M., Tammela, T.L.J. and Visakorpi, T. (2005) Dual-specificity phosphatase 1 and serum/ glucocorticoid-regulated kinase are downregulated in prostate cancer. Int. J. Cancer 117, 738-745 doi:10.1002/ijc.21270
Uzgare, A.R., Kaplan, P.J. and Greenberg, N.M. (2003) Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. Prostate 55, 128-139 doi:10.1002/pros.10212
Frank, S.B. and Miranti, C.K. (2013) Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front. Oncol. 3, 273 doi:10.3389/fonc.2013.00273
Browne, A.J., Göbel, A., Thiele, S., Hofbauer, L.C., Rauner, M. and Rachner, T.D. (2016) p38 MAPK regulates the Wnt inhibitor Dickkopf-1 in osteotropic prostate cancer cells. Cell Death Dis. 7, e2119 doi:10.1038/cddis.2016.32
Manzano, R.G., Montuenga, L.M., Dayton, M., Dent, P., Kinoshita, I., Vicent, S. et al. (2002) CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene 21, 4435-4447 doi:10.1038/sj.onc.1205542
Denkert, C., Schmitt, W.D., Berger, S., Reles, A., Pest, S., Siegert, A. et al. (2002) Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. Int. J. Cancer 102, 507-513 doi:10.1002/ijc.10746
Kang, Y., Nagaraja, A.S., Armaiz-Pena, G.N., Dorniak, P.L., Hu, W., Rupaimoole, R. et al. (2016) Adrenergic stimulation of DUSP1 impairs chemotherapy response in ovarian cancer. Clin. Cancer Res. 22, 1713-1724 doi:10.1158/1078-0432.CCR-15-1275
Li, L., Cai, S., Liu, S., Feng, H. and Zhang, J. (2017) Bioinformatics analysis to screen the key prognostic genes in ovarian cancer. J. Ovarian Res. 10, 27 doi:10.1186/s13048-017-0323-6
Wang, H.y., Cheng, Z. and Malbon, C.C. (2003) Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett. 191, 229-237 doi:10.1016/S0304-3835(02)00612-2
Rojo, F., Gonzalez-Navarrete, I., Bragado, R., Dalmases, A., Menendez, S., Cortes-Sempere, M. et al. (2009) Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. Clin. Cancer Res. 15, 3530-3539 doi:10.1158/1078-0432.CCR-08-2070
Hou, M.-F., Chang, C.-W., Chen, F.-M., Wang, S.-N., Yang, S.-F., Chen, P.-H. et al. (2012) Decreased total MKP-1 protein levels predict poor prognosis in breast cancer. World J. Surg. 36, 1922-1932 doi:10.1007/s00268-012-1608-y
Chen, F.-M., Chang, H.-W., Yang, S.-F., Huang, Y.-F., Nien, P.-Y., Yeh, Y.-T. et al. (2012) The mitogen-activated protein kinase phosphatase-1 (MKP1) gene is a potential methylation biomarker for malignancy of breast cancer. Exp. Mol. Med. 44, 356 doi:10.3858/emm.2012.44.5.040
Li, J., Chen, Y., Yu, H., Tian, J., Yuan, F., Fan, J. et al. (2017) DUSP1 promoter methylation in peripheral blood leukocyte is associated with triple-negative breast cancer risk. Sci. Rep. 7, 43011 doi:10.1038/srep43011
Lin, Y.-M., Jan, H.-J., Lee, C.-C., Tao, H.-Y., Shih, Y.-L., Wei, H.-W. et al. (2008) Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism. Eur. J. Pharmacol. 593, 1-9 doi:10.1016/j.ejphar.2008.06.111
Jan, H.-J., Lee, C.-C., Lin, Y.-M., Lai, J.-H., Wei, H.-W. and Lee, H.-M. (2009) Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells. Cancer Lett. 277, 141-148 doi:10.1016/j.canlet.2008.11.033
Dietrich, J., Rao, K., Pastorino, S. and Kesari, S. (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev. Clin. Pharmacol. 4, 233-242 doi:10.1586/ecp.11.1
Wu, W., Pew, T., Zou, M., Pang, D. and Conzen, S.D. (2005) Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem. 280, 4117-4124 doi:10.1074/jbc.M411200200
Kang, Y.-S., Seok, H.-J., Jeong, E.-J., Kim, Y., Yun, S.-J., Min, J.-K. et al. (2016) DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Biochem. Biophys. Res. Commun. 478, 403-409 doi:10.1016/j.bbrc.2016.07.035
Chattopadhyay, S., Machado-Pinilla, R., Manguan-Garcia, C., Belda-Iniesta, C., Moratilla, C., Cejas, P. et al. (2006) MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer. Oncogene 25, 3335-3345 doi:10.1038/sj.onc.1209364
Melhem, A., Yamada, S.D., Fleming, G.F., Delgado, B., Brickley, D.R., Wu, W. et al. (2009) Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin. Cancer Res. 15, 3196-3204 doi:10.1158/ 1078-0432.CCR-08-2131
Wang, J., Zhou, J.-Y., Zhang, L. and Gen, S.W. (2009) Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells. Cell Cycle 8, 3191-3198 doi:10.4161/cc.8.19.9751
Wang, J., Zhou, J.-Y. and Wu, G.S. (2007) ERK-dependent MKP-1 mediated cisplatin resistance in human ovarian cancer cells. Cancer Res. 67, 11933-11941 doi:10.1158/0008-5472.CAN-07-5185
Wang, Q., Shi, S., He, W., Padilla, M.T., Zhang, L., Wang, X. et al. (2014) Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget 5, 1304-1314 doi:10.18632/oncotarget.1798
Cortes-Sempere, M., Chattopadhyay, S., Rovira, A., Rodriguez-Fanjul, V., Belda-Iniesta, C., Tapia, M. et al. (2009) MKP1 repression is required for the chemosensitizing effects of NF-κB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cancer Lett. 286, 206-216 doi:10.1016/j.canlet.2009.05.029
Liu, F., Gore, A.J., Wilson, J.L. and Korc, M. (2014) DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine. PLoS ONE 9, e84982 doi:10.1371/journal.pone.0084982
Lin, Y.-C., Lin, Y.-C., Shih, J.-Y., Huang, W.-J., Chao, S.-W., Chang, Y.-L. et al. (2015) DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers. Clin. Cancer Res. 21, 428-438 doi:10.1158/1078-0432.CCR-14-1150
Cimas, F.J., Callejas-Valera, J.L., Pascual-Serra, R., García-Cano, J., Garcia-Gil, E., De la Cruz-Morcillo, M.A. et al. (2015) MKP1 mediates chemosensitizer effects of E1a in response to cisplatin in non-small cell lung carcinoma cells. Oncotarget 6, 44095-44107 doi:10.18632/oncotarget.6574
Small, G.W., Shi, Y.Y., Higgins, L.S. and Orlowski, R.Z. (2007) Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance. Cancer Res. 67, 4459-4466 doi:10.1158/0008-5472.CAN-06-2644
Patel, B.S., Co, W.S., Donat, C., Wang, M., Che, W., Prabhala, P. et al. (2015) Repression of breast cancer cell growth by proteasome inhibitors in vitro: impact of mitogen-activated protein kinase phosphatase 1. Cancer Biol. Ther. 16, 780-789 doi:10.1080/15384047.2015.1026465
Ma, G., Pan, Y., Zhou, C., Sun, R., Bai, J., Liu, P. et al. (2015) Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells. Oncol. Rep. 34, 2423-2430 doi:10.3892/or.2015.4244
Haagenson, K.K., Zhang, J.W., Xu, Z., Shekhar, M.P.V. and Wu, G.S. (2014) Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity. Oncotarget 5, 1101-1110 doi:10.18632/oncotarget.1795
Candas, D., Lu, C.-L., Fan, M., Chuang, F.Y.S., Sweeney, C., Borowsky, A.D. et al. (2014) Mitochondrial MKP1 is a target for therapy-resistant HER2-positive breast cancer cells. Cancer Res. 74, 7498-7509 doi:10.1158/0008-5472.CAN-14-0844
Yu, H., Park, J., Lee, J., Choi, K. and Choi, C. (2012) Constitutive expression of MAP kinase phosphatase-1 confers multi-drug resistance in human glioblastoma cells. Cancer Res. Treat. 44, 195-201 doi:10.4143/crt.2012.44.3.195
Park, J., Lee, J., Kang, W., Chang, S., Shin, E.-C. and Choi, C. (2013) TGF-β1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death. Cell Death Dis. 4, e521 doi:10.1038/cddis.2013.42
Molina, G., Vogt, A., Bakan, A., Dai, W., de Oliveira, P.Q., Znosko, W. et al. (2009) Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 5, 680-687 doi:10.1038/nchembio.190
Kaltenmeier, C.T., Vollmer, L.L., Vernetti, L.A., Caprio, L., Davis, K., Korotchenko, V.N. et al. (2017) A tumor cell-selective inhibitor of mitogen-activated protein kinase phosphatases sensitizes breast cancer cells to lymphokine-activated killer cell activity. J. Pharmacol. Exp. Ther. 361, 39-50 doi:10.1124/jpet.116.239756
Boulding, T., Wu, F., McCuaig, R., Dunn, J., Sutton, C.R., Hardy, K. et al. (2016) Differential roles for DUSP family members in epithelial-to-mesenchymal transition and cancer stem cell regulation in breast cancer. PLoS ONE 11, e0148065 doi:10.1371/journal.pone.0148065
Hill, R., Calvopina, J.H., Kim, C., Wang, Y., Dawson, D.W., Donahue T.R. et al. (2010) PTEN loss accelerates Kras-G12D-induced pancreatic cancer development. Cancer Res. 70, 7114-7124 doi:10.1158/0008-5472.CAN-10-1649
Ying, H., Elpek, K.G., Vinjamoori, A., Zimmerman, S.M., Chu, G.C., Yan, H. et al. (2011) PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 1, 158-169 doi:10.1158/2159-8290.CD-11-0031
Huang, W., Yang, J., Ren, J. and Tang, J. (2015) Expression of PTEN and KAI1 tumor suppressor genes in pancreatic carcinoma and its association with different pathological factors. Oncol. Lett. 11, 559-562 doi:10.3892/ol.2015.3932
Tanwar, P.S., Mohapatra, G., Chiang, S., Engler, D.A., Zhang, L., Kaneko-Tarui, T. et al. (2014) Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis 35, 546-553 doi:10.1093/carcin/bgt357
Xu, C., Fillmore, C.M., Koyama, S., Wu, H., Zhao, Y., Chen, Z. et al. (2014) Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated pd-l1 expression. Cancer Cell 25, 590-604 doi:10.1016/j.ccr.2014.03.033
Liu, J.C., Voisin, V., Wang, S., Wang, D.-Y., Jones, R.A., Datti, A. et al. (2014) Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol. Med. 6, 1542-1560 doi:10.15252/emmm.201404402
Minami, A., Nakanishi, A., Ogura, Y., Kitagishi, Y. and Matsuda, S. (2014) Connection between tumor suppressor BRCA1 and PTEN in damaged DNA repair. Front. Oncol. 4, 318 doi: 10.3389/fonc.2014.00318
de Graffenried, L.A., Fulcher, L., Friedrichs, W.E., Grünwald, V., Ray, R.B. and Hidalgo, M. (2004) Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 15, 1510-1516 doi:10.1093/annonc/mdh388
Huang, H., Cheville, J.C., Pan, Y., Roche, P.C., Schmidt, L.J. and Tindall, D.J. (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 276, 38830-38836 doi:10.1074/jbc.M103632200
Wu, H., Cao, Y., Weng, D., Xing, H., Song, X., Zhou, J. et al. (2008) Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett. 271, 260-271 doi:10.1016/j.canlet.2008.06.012
Chen, Q., Qin, R., Fang, Y. and Li, H. (2015) Berberine sensitizes human ovarian cancer cells to cisplatin through miR-93/PTEN/Akt signaling pathway. Cell. Physiol. Biochem. 36, 956-965 doi:10.1159/000430270
Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J.D., Wang, J. et al. (2008) MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 68, 425-433 doi:10.1158/0008-5472.CAN-07-2488
Wang, Y.-S., Wang, Y.-H., Xia, H.-P., Zhou, S.-W., Schmid-Bindert, G. and Zhou, C.-C. (2012) MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines. Asian Pac. J. Cancer Prev. 13, 255-260 doi:10.7314/APJCP.2012.13.1.255
Yin, X., Zhang, N. and Di, W. (2013) Regulation of LC3-dependent protective autophagy in ovarian cancer cells by protein phosphatase 2A. Int. J. Gynecol. Cancer 23, 630-641 doi:10.1097/IGC.0b013e3182892cee
Chang, K.-E., Wei, B.-R., Madigan, J.P., Hall, M.D., Simpson, R.M., Zhuang, Z. et al. (2015) The protein phosphatase 2A inhibitor LB100 sensitizes ovarian carcinoma cells to cisplatin-mediated cytotoxicity. Mol. Cancer Ther. 14, 90-100 doi:10.1158/1535-7163.MCT-14-0496
Bansal, N., Marchion, D.C., Bicaku, E., Xiong, Y., Chen, N., Stickles, X.B. et al. (2012) BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin. J. Gynecol. Oncol. 23, 35-42 doi:10.3802/jgo.2012.23.1.35
Bai, X., Zhi, X., Zhang, Q., Liang, F., Chen, W., Liang, C. et al. (2014) Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. Cancer Lett. 355, 281-287 doi:10.1016/j.canlet.2014.09.048
Wei, D., Parsels, L.A., Karnak, D., Davis, M.A., Parsels, J.D., Marsh, A.C. et al. (2013) Inhibition of protein phosphatase 2A radiosensitizes pancreatic cancers by modulating CDC25C/CDK1 and homologous recombination repair. Clin. Cancer Res. 19, 4422-4432 doi:10.1158/1078-0432. CCR-13-0788
Hung, M.-H., Wang, C.-Y., Chen, Y.-L., Chu, P.-Y., Hsiao, Y.-J., Tai, W.-T. et al. (2016) SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A. Oncotarget 1, 638-655 doi:10.18632/oncotarget.6313
Hu, X., Garcia, C., Fazli, L., Gleave, M., Vitek, M.P., Jansen, M. et al. (2015) Inhibition of Pten deficient castration resistant prostate cancer by targeting of the SET-PP2A signaling axis. Sci. Rep. 5, 15182 doi:10.1038/srep15182
Liu, C.-Y., Hung, M.-H., Wang, D.-S., Chu, P.-Y., Su, J.-C., Teng, T.-H. et al. (2014) Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells. Breast Cancer Res. 16, 431 doi:10.1186/s13058-014-0431-9
McDermott, M.S.J., Browne, B.C., Conlon, N.T., O'Brien, N.A., Slamon, D.J., Henry, M. et al. (2014) PP2A inhibition overcomes acquired resistance to HER2 targeted therapy. Mol. Cancer 13, 157 doi:10.1186/1476-4598-13-157
Santra, M., Santra, S., Roberts, C., Zhang, R.L. and Chopp, M. (2009) Doublecortin induces mitotic microtubule catastrophe and inhibits glioma cell invasion. J. Neurochem. 108, 231-245 doi:10.1111/j.1471-4159.2008.05758.x
Ladha, J., Donakonda, S., Agrawal, S., Thota, B., Srividya, M.R., Sridevi, S. et al. (2010) Glioblastoma-specific protein interaction network identifies PP1A and CSK21 as connecting molecules between cell cycle-associated genes. Cancer Res. 70, 6437-6447 doi:10.1158/0008-5472.CAN-10-0819
Kim, W., Youn, H., Kang, C. and Youn, B. (2015) Inflammation-induced radioresistance is mediated by ROS-dependent inactivation of protein phosphatase 1 in non-small cell lung cancer cells. Apoptosis 20, 1242-1252 doi:10.1007/s10495-015-1141-1
Xie, M., Zhou, L., Chen, X., Gainey, L.O., Xiao, J., Nanes, M.S. et al. (2015) Progesterone and Src family inhibitor PP1 synergistically inhibit cell migration and invasion of human basal phenotype breast cancer cells. Biomed. Res. Int. 2015, 426-429 doi:10.1155/2015/426429
Winter, S.L., Bosnoyan-Collins, L., Pinnaduwage, D. and Andrulis, I.L. (2007) The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors. BMC Cancer 7, 85 doi:10.1186/1471-2407-7-85
Yu, Y.-M., Pace, S.M., Allen, S.R., Deng, C.-X. and Hsu, L.-C. (2008) A PP1-binding motif present in BRCA1 plays a role in its DNA repair function. Int. J. Biol. Sci. 4, 352-361 doi:10.7150/ijbs.4.352
Li, M., Li, X., Xu, S., Xue, P., Li, Q., Lu, Q. et al. (2016) Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion. Tumor Biol. 37, 11893-11901 doi:10.1007/s13277-016-5054-6
Weng, S., Wang, H., Chen, W., Katz, M.H., Chatterjee, D., Lee, J.E. et al. (2012) Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol. Biomarkers Prev. 21, 1336-1343 doi:10.1158/1055-9965.EPI-12-0223
Wang, B., Zhao, A., Sun, L., Zhong, X., Zhong, J., Wang, H. et al. (2008) Protein phosphatase PP4 is overexpressed in human breast and lung tumors. Cell Res. 18, 974-977 doi:10.1038/cr.2008.274
Zhi, X., Zhang, H., He, C., Wei, Y., Bian, L. and Li, G. (2015) Serine/threonine protein phosphatase-5 accelerates cell growth and migration in human glioma. Cell. Mol. Neurobiol. 35, 669-677 doi:10.1007/s10571-015-0162-1
Zheng, X., Zhang, L., Jin, B., Zhang, F., Zhang, D. and Cui, L. (2016) Knockdown of protein phosphatase 5 inhibits ovarian cancer growth in vitro. Oncol. Lett. 11, 168-172 doi:10.3892/ol.2015.3828
Golden, T., Aragon, I.V., Rutland, B., Tucker, J.A., Shevde, L.A., Samant, R.S. et al. (2009) Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer. Biochim. Biophys. Acta Mol. Basis Dis. 1782, 259-270 doi:10.1016/j.bbadis.2008.01.004
Shen, Y., Wang, Y., Sheng, K., Fei, X., Guo, Q., Larner, J. et al. (2011) Serine/threonine protein phosphatase 6 modulates the radiation sensitivity of glioblastoma. Cell Death Dis. 2, e241 doi:10.1038/cddis.2011.126
Qian, Y., Ma, J., Guo, X., Sun, J., Yu, Y., Cao, B. et al. (2015) Curcumin enhances the radiosensitivity of U87 cells by inducing DUSP-2 up-regulation cellular physiology and biochemistry cellular physiology and biochemistry. Cell. Physiol. Biochem. 35, 1381-1393 doi:10.1159/000373959
Zhang, L., Ding, X., Huang, J., Jiang, C., Cao, B., Qian, Y. et al. (2015) In vivo radiosensitization of human glioma U87 cells induced by upregulated expression of DUSP-2 after treatment with curcumin. Curr. Signal. Transduct. Ther. 10, 119-125 doi:10.2174/1574362410666150109223303
Karakashev, S.V. and Reginato, M.J. (2015) Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget 6, 1967-1980 doi:10.18632/oncotarget.2806
Givant-Horwitz, V., Davidson, B., Goderstad, J.M., Nesland, J.M., Tropé, C.G. and Reich, R. (2004) The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol. Oncol. 93, 517-523 doi:10.1016/j.ygyno.2004.03.009
Halatsch, M.-E., Löw, S., Mursch, K., Hielscher, T., Schmidt, U., Unterberg, A. et al. (2009) Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J. Neurosurg. 111, 211-218 doi:10.3171/2008.9.JNS08551
Waha, A., Felsberg, J., Hartmann, W., Von Dem Knesebeck, A., Mikeska, T., Joos, S. et al. (2010) Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 70, 1689-1699 doi:10.1158/0008-5472.CAN-09-3218
Chitale, D., Gong, Y., Taylor, B.S., Broderick, S., Brennan, C., Somwar, R. et al. (2009) An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28, 2773-2783 doi:10.1038/onc.2009.135
Sieben, N.L.G., Oosting, J., Flanagan, A.M., Prat, J., Roemen, G.M.J.M., Kolkman-Uljee, S.M. et al. (2005) Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J. Clin. Oncol. 23, 7257-7264 doi:10.1200/ JCO.2005.02.2541
Baglia, M.L., Cai, Q., Zheng, Y., Wu, J., Su, Y., Ye, F. et al. (2014) Dual specificity phosphatase 4 gene expression in association with triple-negative breast cancer outcome. Breast Cancer Res. Treat. 148, 211-220 doi:10.1007/s10549-014-3127-z
Mazumdar, A., Poage, G.M., Shepherd, J., Tsimelzon, A., Hartman, Z.C., Den Hollander, P. et al. (2016) Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res. Treat. 158, 441-454 doi:10.1007/s10549-016-3892-y
Balko, J.M., Schwarz, L.J., Bhola, N.E., Kurupi, R., Owens, P., Miller, T.W. et al. (2013) Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73, 6346-6358 doi:10.1158/0008-5472.CAN-13-1385
Balko, J.M., Cook, R.S., Vaught, D.B., Kuba, M.G., Miller, T.W., Bhola, N.E. et al. (2012) Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052-1059 doi:10.1038/nm.2795
Liu, Y., Du, F., Chen, W., Yao, M., Lv, K. and Fu, P. (2013) Knockdown of dual specificity phosphatase 4 enhances the chemosensitivity of MCF-7 and MCF-7/ADR breast cancer cells to doxorubicin. Exp. Cell Res. 319, 3140-3149 doi:10.1016/j.yexcr.2013.08.023
Jung, H.H., Lee, S.-H., Kim, J.-Y., Ahn, J.S., Park, Y.H. and Im, Y.-H. (2016) Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency. Sci. Rep. 6, 33035 doi:10.1038/srep33035
Kim, H., Jang, S.M., Ahn, H., Sim, J., Yi, K., Chung, Y. et al. (2015) Breast cancer clinicopathological significance of dual-specificity protein phosphatase 4 expression in invasive ductal carcinoma of the breast. J. Breast Cancer 18, 1-7 doi:10.4048/jbc.2015.18.1.1
Yip-Schneider, M.T., Lin, A. and Marshall, M.S. (2001) Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem. Biophys. Res. Commun. 280, 992-997 doi:10.1006/bbrc.2001.4243
Hijiya, N., Tsukamoto, Y., Nakada, C., Tung Nguyen, L., Kai, T., Matsuura, K. et al. (2016) Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma. Cancer Res. 76, 2612-2625 doi:10.1158/0008-5472.CAN-15-1846
Cai, C., Chen, J.-Y., Han, Z., He, H., Chen, J.-H., Chen, Y. et al. (2015) Down-regulation of dual-specificity phosphatase 5 predicts poor prognosis of patients with prostate cancer. Int. J. Clin. Exp. Med. 8, 4186-4194 PMID:26064329
Messina, S., Frati, L., Leonetti, C., Zuchegna, C., Di Zazzo, E., Calogero, A. et al. (2011) Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30, 3813-3820 doi:10.1038/onc.2011.99
Zhai, X., Han, Q., Shan, Z., Qu, X., Guo, L. and Zhou, Y. (2014) Dual specificity phosphatase 6 suppresses the growth and metastasis of prostate cancer cells. Mol. Med. Rep. 10, 3052-3058 doi:10.3892/mmr.2014.2575
Chan, D.W., Liu, V.W.S., Tsao, G.S.W., Yao, K.-M., Furukawa, T., Chan, K.K.L. et al. (2008) Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29, 1742-1750 doi:10.1093/carcin/bgn167
Díaz-García, C.V., Agudo-López, A., Pérez, C., Prieto-García, E., Iglesias, L., Ponce, S. et al. (2015) Prognostic value of dual-specificity phosphatase 6 expression in non-small cell lung cancer. Tumour Biol. 36, 1199-1206 doi:10.1007/s13277-014-2729-8
Furukawa, T., Yatsuoka, T., Youssef, E.M., Abe, T., Yokoyama, T., Fukushige, S. et al. (1998) Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet. Genome Res. 82, 156-159 doi:10.1159/000015091
Lucci, M.A., Orlandi, R., Triulzi, T., Tagliabue, E., Balsari, A. and Villa-Moruzzi, E. (2010) Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol. 32, 361-372 doi:10.3233/CLO-2010-0520
Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S.G., Tsimelzon, A., Furukawa, T. et al. (2006) Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 66, 5950-5959 doi:10.1158/0008-5472.CAN-05-3243
Zhang, H., Zhu, W., Su, X., Wu, S., Lin, Y., Li, J. et al. (2012) Triptolide inhibits proliferation and invasion of malignant glioma cells. J. Neurooncol. 109, 53-62 doi:10.1007/s11060-012-0885-5
Han, M.H., Kim, S.O., Kim, G.Y., Kwon, T.K., Choi, B.T., Lee, W.H. et al. (2007) Induction of apoptosis by sanguinarine in C6 rat glioblastoma cells is associated with the modulation of the Bcl-2 family and activation of caspases through downregulation of extracellular signal-regulated kinase and Akt. Anticancer Drugs 18, 913-921 doi:10.1097/CAD.0b013e328117f463
